In addition, MSLN-specific intracellular cytokine staining and MSLN-specific CTL assays further confirmed that mMSLN-VLP immunization has the ability to induce a MSLN-specific CD8+ T cell response which is beneficial for suppressing tumor growth. The gene discussed is CD8A; the disease is neoplasm.